We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+12.81%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$225M
AUM Growth
-$5.82M
(-2.5%)
Cap. Flow
-$29.2M
Cap. Flow
% of AUM
-12.97%
Top 10 Holdings %
Top 10 Hldgs %
45.19%
Holding
92
New
27
Increased
21
Reduced
24
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$5.69M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
+$5.36M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$5.15M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$4.63M |
| 5 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$4.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$11.9M |
| 2 |
Abbott
ABT
|
+$11.6M |
| 3 |
Johnson & Johnson
JNJ
|
+$7.46M |
| 4 |
Universal Health Services
UHS
|
+$7.16M |
| 5 |
AGN
Allergan plc
AGN
|
+$6.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.74% |
| 2 | Industrials | 2.11% |
| 3 | Financials | 2.08% |
| 4 | Technology | 0.89% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Gilead Sciences
GILD
$163B
| $796K | 0.35% |
10,315
-72,548
| -88% | -$5.48M |
|
|
ESRX
52
DELISTED
Express Scripts Holding Company
ESRX
| $789K | 0.35% |
8,305
-14,985
| -64% | -$1.28M |
|
|
VRAY
53
DELISTED
ViewRay, Inc.
VRAY
| $711K | 0.32% |
+75,971
| New | +$747K |
|
54
Acadia Pharmaceuticals
ACAD
$4.39B
| $672K | 0.3% |
+32,371
| New | +$509K |
|
55
Becton Dickinson
BDX
$46.9B
| $672K | 0.3% |
2,640
-14,648
| -85% | -$3.61M |
|
56
Orthofix Medical
OFIX
$496M
| $664K | 0.3% |
+11,478
| New | +$643K |
|
57
Edwards Lifesciences
EW
$51.1B
| $663K | 0.29% |
+11,418
| New | +$558K |
|
58
Liquidia Corp
LQDA
$7.46B
| $661K | 0.29% |
+24,085
| New | +$396K |
|
59
Jazz Pharmaceuticals
JAZZ
$15.8B
| $618K | 0.27% |
+3,674
| New | +$632K |
|
|
IMGN
60
DELISTED
Immunogen Inc
IMGN
| $607K | 0.27% |
64,065
-4,200
| -6% | -$40.4K |
|
|
CLSD
61
DELISTED
Clearside Biomedical
CLSD
| $580K | 0.26% |
6,284
+4,324
| +221% | +$514K |
|
|
OMED
62
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $465K | 0.21% |
+219,114
| New | +$525K |
|
63
LivaNova
LIVN
$4.53B
| $459K | 0.2% |
+3,703
| New | +$437K |
|
|
SPPI
64
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $446K | 0.2% |
+26,534
| New | +$574K |
|
|
AKTX
65
Akari Therapeutics
AKTX
$12.9M
| $419K | 0.19% |
205
-20
| -9% | -$32.3K |
|
|
ARA
66
DELISTED
American Renal Associates Holdings, Inc
ARA
| $397K | 0.18% |
+18,340
| New | +$347K |
|
67
McKesson
MCK
$96.8B
| $374K | 0.17% |
2,822
-9,957
| -78% | -$1.3M |
|
|
68
Johnson & Johnson
JNJ
$613B
| $341K | 0.15% |
2,469
-56,158
| -96% | -$7.46M |
|
69
Axsome Therapeutics
AXSM
$10.9B
| $328K | 0.15% |
+95,185
| New | +$282K |
|
|
WBA
70
DELISTED
Walgreens Boots Alliance
WBA
| $261K | 0.12% |
3,581
-25,567
| -88% | -$1.74M |
|
71
Ocugen
OCGN
$423M
| $22K | 0.01% |
666
-270
| -29% | -$31.3K |
|
72
Centene
CNC
$31.5B
| – | – |
-35,222
| Closed | -$2.17M |
|
73
Cooper Companies
COO
$14.5B
| – | – |
-37,768
| Closed | -$2.22M |
|
74
Cencora
COR
$60B
| – | – |
-3,692
| Closed | -$315K |
|
75
HCA Healthcare
HCA
$88B
| – | – |
-30,755
| Closed | -$3.15M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q3 2018 Portfolio in Review
As of Q3 2018, Endurant Capital Management held 92 positions worth $225M, down 2.5% from $231M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Endurant Capital Management withdrew a net $29.2M in Q3 2018, closing 19 positions and reducing 24 holdings. Its most notable exit was Universal Health Services, an estimated $7.16M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Industrials and Financials.
Against the trend, Endurant Capital Management opened a new position in Sanofi worth $5.95M.
- Endurant Capital Management's largest Q3 2018 buy was Sanofi: 133,245 shares worth $5.95M.
- Endurant Capital Management added most to Wright Medical Group Inc in Q3 2018, an estimated $5.36M increase.
- Endurant Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $11.9M.
- Endurant Capital Management fully exited Universal Health Services in Q3 2018, selling an estimated $7.16M.
- Endurant Capital Management's ten largest holdings make up 45% of its $225M portfolio in Q3 2018.
- Endurant Capital Management opened 27 new positions and closed 19 in Q3 2018.
- Endurant Capital Management's portfolio value fell 2.5% quarter-over-quarter to $225M.
Based on Endurant Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.